Akshit Chitkara, MD, discusses outcomes with IO doublet therapy by dedifferentiation status and histologic grade in ccRCC.
Akshit Chitkara, MD
Advertisement
Akshit Chitkara, MD, is a hematology-oncology fellow at Sidney Kimmel Cancer Center.
Articles by Akshit Chitkara, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
Sonesitatug Vedotin Improves Overall Survival in Second- and Later-Line CLDN18.2-Positive Gastric/GEJ Cancer
3
Volume, Biomarkers, and Cost Realities Guide ARPI Sequencing in Advanced Prostate Cancer
4
Updated Safusidenib Data Show Durable Responses in Grade 2 IDH1-Mutant Glioma
5